Christian Behrenbruch, MD & Group CEO at Telix Pharmaceuticals Ltd (TLX), bought 67,935 shares at $14.48 ($997K) on 2026-04-28, disclosed to the SEC on 2026-05-06.
Telix Pharmaceuticals Group CEO Christian Behrenbruch purchased $500k of stock at $14.48 per share, marking the largest purchase of his career. This significant insider buying comes as the stock rallies 21.87% over the last 30 days and nears its 52-week high.
The shares are currently trading at $11.09, up 21.87% over the past month and just 1.86% below the 52-week high of $11.30.
Management is set to present clinical trial data for its prostate cancer drug candidate on April 21; Phase 2 OPTIMAL-PSMA dosimetry results were released on April 30; and the company hosted a webinar on April 30 outlining its next-gen PSMA strategy.
The stock trades at a forward P/E of 40.01, which is a high valuation multiple for a commercial-stage biopharmaceutical.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.48 | 34,500 | $500K | 50.1% |
| 2 | $14.87 | 33,435 | $497K | 49.9% |
| Total | $14.67 avg | 67,935 | $997K | 100% |